The Condition With Zero Drugs Just Found Its First Lead
A University of Michigan team just proved that triglycerides directly cause a deadly condition with zero approved drugs, then showed they could prevent it in mice. The finding could unlock an entirely new class of treatment for 200,000 Americans a year.
Right now, roughly 200,000 Americans get diagnosed with an abdominal aortic aneurysm every year. Their aorta, the body's main highway for blood, slowly balloons outward like a weak spot on an old tire. If it ruptures, more than 80% of them die.
And the number of FDA-approved drugs to stop it from happening? Zero.
Doctors can monitor the bulge with ultrasounds. They can recommend quitting smoking and eating better. Once it gets dangerous enough (usually around 5.5 centimeters wide), surgeons can install a stent or cut you open to replace the damaged section entirely. But there's nothing you can swallow, inject, or infuse to slow the thing down. It's like knowing the dam is cracking and having no concrete to patch it.
That might be about to change.
A Bracket Tournament for Nerds (With 168,000 Votes)
Every year, STAT News runs something called STAT Madness: a 64-team, bracket-style tournament where biomedical research teams compete for the title of top innovation. Think March Madness, but instead of buzzer-beaters, you get breakthroughs in gene therapy, Alzheimer's detection, and AI-powered cell models. Winners are chosen by popular vote, and the 2026 edition drew over 168,000 votes across six rounds.
A team from the University of Michigan Frankel Cardiovascular Center, led by Dr. Eugene Chen, reached the final round with 58% of the vote against Florida International University. FIU's entry was no slouch either: a machine-learning approach to spotting early Alzheimer's markers in brain tissue. But Michigan's paper offered something the field has been missing for decades: a direct, causal explanation for why abdominal aortic aneurysms happen, and a potential way to stop them.
The Culprit Hiding in Your Bloodwork
For years, scientists knew that people with abdominal aortic aneurysms (AAA) tended to have high triglycerides, a type of fat in your blood that spikes after you eat. But correlation isn't causation. Lots of AAA patients also smoke, have high blood pressure, and carry other cardiovascular risk factors. Triglycerides could've been a bystander, just another number that tended to be elevated in people who were already unhealthy.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Michigan's team set out to prove the relationship was real. Their paper, published in Circulation in September 2025, used genetically modified mice (specifically, APOC3 transgenic and Apoe-deficient strains) to untangle the question. These mice were engineered to have sky-high triglyceride levels, which let the researchers study what happens when you crank that one variable up while controlling for everything else.
The answer: triglycerides don't just tag along. They actively drive aneurysm formation. The team identified a specific mechanism involving lysyl oxidase (LOX), an enzyme your body uses to cross-link collagen and elastin in blood vessel walls. Think of LOX as the rivets holding together the steel beams of a bridge. High triglycerides impair LOX function, weakening those rivets. Over time, the aortic wall loses structural integrity and starts to bulge.
That's the "why." But the team didn't stop there.
A Drug That Actually Worked (in Mice)
Once you know triglycerides are the problem, the next question is obvious: what happens if you lower them?
The Michigan researchers tested an antisense oligonucleotide (ASO) targeting a protein called ANGPTL3. In plain English, an ASO is a short strand of synthetic genetic material designed to intercept a specific messenger molecule before it can tell your cells to make a protein. In this case, the ASO blocks the instructions for ANGPTL3, a protein that normally keeps triglyceride levels elevated by interfering with the enzymes that clear fat from your blood.
Blocking ANGPTL3 in the mouse models reduced triglyceride levels by up to 50%. More importantly, it prevented aneurysms from forming. The mice that received the treatment didn't just have better bloodwork; their aortas stayed intact.
This is a big deal. Not "we slowed progression by a few percent" big. Not "we saw a trend toward improvement" big. The treatment profoundly attenuated AAA progression in these models.
Now, the obligatory caveat: mice are not people. The graveyard of drug development is littered with therapies that worked beautifully in rodents and then flopped in human trials. But the strength of this finding is in the mechanistic clarity. The team didn't just show that something worked; they showed why it worked, tracing the chain from high triglycerides to impaired LOX to weakened vessel walls to aneurysm formation. That kind of clear biological logic makes the leap to humans more plausible.
ANGPTL3: A Target With a Head Start
The good news for anyone hoping this research translates to humans? ANGPTL3 isn't some obscure, untested target. Several companies are already developing therapies against it for other cardiovascular conditions.
Vupanorsen, an ASO developed by Ionis Pharmaceuticals (later licensed to Pfizer), targets ANGPTL3 and has been in clinical development for lowering triglycerides and LDL cholesterol. Arrowhead Pharmaceuticals is working on zodasiran, an RNA-based therapy that blocks the same protein through a slightly different mechanism (siRNA instead of ASO). In Phase 2 trials, zodasiran reduced triglycerides by 63% and LDL cholesterol by 20%, with Phase 3 trials planned.
There's also evinacumab, a monoclonal antibody already approved by the FDA for a rare cholesterol disorder called homozygous familial hypercholesterolemia (HoFH). It works by neutralizing the ANGPTL3 protein directly.
So the infrastructure exists. The target is validated. The question now is whether anyone will run a clinical trial specifically testing one of these therapies in AAA patients. That would be a first: an actual drug trial for a condition that currently has no pharmacological options whatsoever.
Why This Matters Beyond One Condition
The Michigan finding plugs into a broader scientific story about triglycerides and cardiovascular disease. For decades, cholesterol (specifically LDL, the "bad" kind) dominated the conversation. Statins became one of the most prescribed drug classes by targeting it. Triglycerides, meanwhile, were treated as a secondary concern; something to keep an eye on, but not a primary driver of disease.
That narrative has been shifting. Mendelian randomization studies (which use genetic variants as natural experiments to infer causation) have shown that elevated triglycerides, particularly in remnant lipoproteins, causally increase the risk of atherosclerotic cardiovascular disease. One study found that a genetic predisposition to lower triglycerides was associated with roughly half the risk of all-cause mortality.
Michigan's AAA paper adds another chapter to this story. Triglycerides aren't just a marker of metabolic dysfunction; they're an active participant in vascular damage. And if that's true for the aorta, it raises questions about what else they might be doing throughout the body.
The Road From Mouse to Medicine
Let's be clear about where things stand. This is a preclinical discovery, meaning it was proven in animal models but hasn't been tested in humans for this specific condition. The path from here to an approved AAA drug would take years and cost hundreds of millions of dollars.
But the pieces are lining up in an unusual way. You have a well-characterized target (ANGPTL3), multiple drug candidates already in human trials for related conditions, a clear mechanism of action, and a disease with zero approved treatments. That combination doesn't come along often.
For the 200,000 Americans diagnosed with AAA each year, the current reality is a waiting game: watch the aneurysm grow, manage your risk factors, and hope it doesn't rupture before it's big enough to warrant surgery. Michigan's research suggests there might eventually be a better option. Not just watching the tire bulge, but actually reinforcing the rubber.
A bracket-style popularity contest isn't the same as peer review. But sometimes the crowd spots something important. And 168,000 voters just said this might be the most important biomedical finding of the year.
Funding & Financings
5 min read
$137 Million for a Cancer Drug That Doesn't Exist Yet
Sidewinder Therapeutics just raised $137 million without ever dosing a patient. Its bispecific ADC platform has big pharma's venture arms lining up, and the math behind the bet says a lot about where oncology dealmaking is headed.
